WP
SGMO

Woodline Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Woodline Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,859
Closed -$19.4K – 1105
2025
Q3 		$19.4K Hold
28,859
– – ﹤0.01% 870
2025
Q2 		$15.6K Buy
28,859
+9,619
+50% +$5.71K ﹤0.01% 910
2025
Q1 		$12.6K Buy
+19,240
New +$20.4K ﹤0.01% 891

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Woodline Partners's SGMO Position: Q4 2025 in Review

Woodline Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 28,859 shares — an estimated $19.4K sold.

Woodline Partners first reported a position in SGMO in Q1 2025 and held it in 3 quarters. The position peaked at $19.4K in Q3 2025. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.

  • Woodline Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
  • Woodline Partners sold 28,859 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $19.4K.
  • Woodline Partners first reported a position in SANGAMO THERAPEUTICS INC in Q1 2025 and held it in 3 quarters.
  • Woodline Partners's SANGAMO THERAPEUTICS INC position peaked at $19.4K in Q3 2025.
  • 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.

Based on Woodline Partners's 13F filing for Q4 2025, filed 17 Feb 2026.